Hematological and biochemical evaluation of beta-thalassemia major (beta TM) patients in Gaza Strip: A cross-sectional study

被引:0
作者
Ayyash, Hani [1 ]
Sirdah, Mahmoud [2 ]
机构
[1] European Gaza Hosp, Dept Hematol, Khanyounis, Gaza Strip, Palestine
[2] Al Azhar Univ Gaza, Fac Sci, Dept Biol, POB 1277, Gaza, Palestine
来源
INTERNATIONAL JOURNAL OF HEALTH SCIENCES-IJHS | 2018年 / 12卷 / 06期
关键词
Chelation therapy; iron overload; splenectomy; transfusion; beta-thalassemia major;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: In Gaza Strip. Palestine, beta-thalassemia is a major public health problem where more than 300 beta-thalassemia major (beta TM) patients are currently being managed at governmental hospitals. We set up to evaluate the hematological and biochemical aspects of our beta TM patients at the Gaza European hospital and their correlation with iron overload. Methods: Our study included 65 transfusion-dependent beta TM, as well as 37 apparently healthy subjects as control group. The hematological and biochemical evaluations included complete blood count, coagulation profile liver and kidney function tests. fasting blood sugar, lipid profile, and serum ferritin. Results: Deteriorated hematological and biochemical statuses were reported in both males and females of beta TM patients as compared to the control group. Statistical comparisons showed no significant differences between males and females beta TM patients in all parameters except for total cholesterol. The results concerning the splenectomized versus non-splenectomized patients revealed significantly higher values in splenectomized patients for white blood cell (WBC), platelet, aspartate aminotransferase, akmine aminotransferase, alkaline phosphatase, albumin. total protein, cholesterol, and potassium concentration compared to the non-splenectomized patients. Patients infected with hepatitis C virus and/or hepatitis B virus showed significant decrease in WBC count as compared to infection free patients, while for serum urea and creatinine. the virally infected beta TM patients revealed significantly higher values compared to infection free patients. Conclusion: This study justified the necessity for strengthening the efforts for regular evaluation and follow-up of the beta TM patients which could be used to improve or modify the management protocols and thus ameliorating their deteriorated hematological and biochemical status.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 41 条
  • [1] Splenectomy for patients with beta-thalassemia major: long-term outcomes
    Ammar, Samir A.
    Elsayh, Khalid I.
    Zahran, Asmaa M.
    Embaby, Mostafa
    [J]. EGYPTIAN JOURNAL OF SURGERY, 2014, 33 (04) : 232 - 236
  • [2] Genotype-Phenotype Correlations of β-Thalassemia Mutations in an Azerbaijani Population
    Asadov, Chingiz
    Abdulalimov, Eldar
    Mammadova, Tahira
    Gafarova, Surmaya
    Guliyeva, Yegana
    Aliyeva, Gunay
    [J]. TURKISH JOURNAL OF HEMATOLOGY, 2017, 34 (03) : 258 - 263
  • [3] A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
    Cappellini, Maria Domenica
    Porter, John B.
    Viprakasit, Vip
    Taher, Ali T.
    [J]. BLOOD REVIEWS, 2018, 32 (04) : 300 - 311
  • [4] Colah KI, 2018, PEDIATR HEMAT ONCOL, V2, P79
  • [5] Beta-thalassemia: from genotype to phenotype
    Danjou, Fabrice
    Anni, Franco
    Galanello, Renzo
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (11): : 1573 - 1575
  • [6] The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major
    Di Maggio, Rosario
    Maggio, Aurelio
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (05) : 676 - 688
  • [7] HbVar Database of Human Hemoglobin Variants and Thalassemia Mutations: 2007 Update
    Giardine, Belinda
    van Baal, Sjozef
    Kaimakis, Polynikis
    Riemer, Cathy
    Miller, Webb
    Samara, Maria
    Kollia, Panagoula
    Anagnou, Nicholas P.
    Chui, David H. K.
    Wajcman, Henri
    Hardison, Ross C.
    Patrinos, George P.
    [J]. HUMAN MUTATION, 2007, 28 (02) : 206
  • [8] Hashemizadeh H, 2012, IRAN J PEDIATR HEMAT, V2, P171
  • [9] HOROWITZ J, 1992, AM SURGEON, V58, P387
  • [10] Khan Palwasha N, 2009, Proc (Bayl Univ Med Cent), V22, P9